Metrics
Publication
4
UN Sustainable Development Goals
Articles
All (2)
SCI-E, SSCI, AHCI (1)
SCI-E, SSCI, AHCI, ESCI (2)
ESCI (1)
Scopus (2)
2025
20251. Real World Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Liver Transplant Recipients
Bektas E., Yilmaz A., Kikili C. I., Nuriyev K., Istemihan Z., Senkal I. V., et al.
Transplant Infectious Disease
, vol.27, no.5, 2025 (SCI-Expanded)
2025
20252. Virological and Biochemical Effects of Tenofovir Alafenamide in Different Patient Groups With Chronic Hepatitis B Virus Infection in Real-World Cohort
Bektas E., Yilmaz A., Kikili C. I., Nuriyev K., Istemihan Z., Senkal I. V., et al.
International Journal of Hepatology
, vol.2025, no.1, 2025 (ESCI)
Papers Presented at Peer-Reviewed Scientific Conferences
2022
20221. Real-world data of tenofovir alafenamide in treatment-naive and experienced patients with Chronic Hepatitis B: more efficacy, less side effects
Bektaş E., Yılmaz A., Kıkılı C. İ., Nurıyev K., İstemihan Z., Şenkal İ. V., et al.
39. Ulusal Gastroenteroloji Haftası ve 10. Gastroenteroloji Cerrahisi Kongresi, Antalya, Turkey, 22 - 27 November 2022, pp.1159-1162, (Summary Text)
2022
20222. REAL-WORLD DATA OF TENOFOVIR ALAFENAMIDE IN TREATMENT-NAIVE AND EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS B: MORE EFFICACY, LESS SIDE EFFECTS
Bektaş E., Yılmaz A., Kıkılı C. İ., Nurıyev K., İstemihan Z., Şenkal İ. V., et al.
AASLD Liver Meeting , District Of Columbia, United States Of America, 4 - 08 November 2022, vol.76, pp.299, (Summary Text)